Announcement PDF ASX Announcement 27 May 2025 APPENDIX 3Y Melbourne, Australia, 27 May 2025: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), submits the Appendix 3Y of Dr Gregory Collier, Dr Ross Murdoch, Mr Matthew McNamara, Ms Katherine Connell. For enquiries, please contact Ms Melanie Leydin Company Secretary Avecho Biotechnology Limited +61 3 9002 5000 This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited. About Avecho Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM ®). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho’s lead asset is a proprietary cannabidiol (“CBD”) TPM soft-gel capsule demonstrated to increase CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for the treatment of insomnia. See more here - avecho.com.au Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Avecho Biotechnology Limited ABN 32 056 482 403 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Gregory Collier Date of last notice 2 December 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Barwon Biotechnology Pty Ltd Note: Provide details of the circumstances giving rise to the relevant interest. Dr Collier is a Director and Shareholder of this entity. 27 May 2025 Date of change No. of securities held prior to change Class Number acquired + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Indirect Beacon Super Fund Pty Ltd <Beacon Super Fund A/c> 1. 4,000,000 Fully Paid Ordinary Shares (AVE) 2. 3,000,000 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Barwon Biotechnology Pty Ltd 1. 5,833,333 Fully Paid Ordinary Shares (AVE) 2. 8,749,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Unquoted options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) 6,338,595 Appendix 3Y Change of Director’s Interest Notice Number disposed Nil Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Indirect Beacon Super Fund Pty Ltd <Beacon Super Fund A/c> 1. 4,000,000 Fully Paid Ordinary Shares (AVE) 2. 3,000,000 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Barwon Biotechnology Pty Ltd 1. 5,833,333 Fully Paid Ordinary Shares (AVE) 2. 8,749,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) 3. 6,338,595 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of unquoted Options following Shareholders approval at the 2025 Annual General Meeting. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Avecho Biotechnology Limited ABN 32 056 482 403 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Ross Murdoch Date of last notice 2 December 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 27 May 2025 No. of securities held prior to change Direct 1. 3,333,333 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Class Unquoted options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Number acquired 3,169,298 Number disposed Nil Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change Direct 1. 3,333,333 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) 3. 3,169,298 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Nature of change Issue of unquoted Options following Shareholders approval at the 2025 Annual General Meeting. Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Avecho Biotechnology Limited ABN 32 056 482 403 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Matthew Patrick McNamara Date of last notice 2 December 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Pelehj145 Pty Ltd <M&L McNamara Super Fund> Note: Provide details of the circumstances giving rise to the relevant interest. Mr McNamara is a director and shareholder of the entity. He is also a beneficiary of the super fund. 27 May 2025 Date of change No. of securities held prior to change Indirect MLAKS PTY LIMITED <M & L MCNAMARA SUPER A/C> 1. 1,666,666 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Class Unquoted options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Number acquired 3,169,298 Number disposed Nil + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Indirect MLAKS PTY LIMITED <M & L MCNAMARA SUPER A/C> 1. 1,666,666 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Pelehj145 Pty Ltd <M&L McNamara Super Fund> 1. 3,169,298 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of unquoted Options following Shareholders approval at the 2025 Annual General Meeting. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Avecho Biotechnology Limited ABN 32 056 482 403 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Katherine Ellen Danielle Connell Date of last notice 26 April 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 27 May 2025 No. of securities held prior to change 3,993,644 Unquoted Options at an exercise price of $0.0056 each, expiring on 26 October 2027 (AVEAS) Class Unquoted options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Number acquired 3,169,298 Number disposed Nil Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change 1. 2. Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back 3,993,644 Unquoted Options at an exercise price of $0.0056 each, expiring on 26 October 2027 (AVEAS) 3,169,298 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Issue of unquoted Options following Shareholders approval at the 2025 Annual General Meeting. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which N/A interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011